DIRAS2 modulates MAPK pathway-mediated ferroptosis to regulate excitation/inhibition balance and seizure

Chenlu Zhang1,2,3,4,5, Liqin Hu6, Hui Zhang2,3,4,5

  • 1The First Clinical Medical College of Shanxi Medical University, Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030000, China.

Insights

DIRAS2, a protein, plays a key role in epilepsy by regulating neuronal excitation/inhibition balance and ferroptosis. Upregulating DIRAS2 may offer a new therapeutic target for epilepsy treatment.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Epilepsy is linked to an imbalance in neuronal excitation and inhibition (E/I).
  • The role of DIRAS2, a Ras-related GTPase, in the nervous system is not well understood.
  • DIRAS2's specific function in epilepsy pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the role and function of DIRAS2 in epilepsy.
  • To explore the therapeutic potential of DIRAS2 in epilepsy treatment.
  • To elucidate the molecular mechanisms underlying DIRAS2's effects in epilepsy.

Main Methods:

  • Kainic acid-induced epilepsy model in mice.
  • Whole-cell patch-clamp recordings.
  • Quantitative proteomic analysis.
  • Ferroptosis inhibition studies using Ferrostatin-1.
  • Analysis of signaling pathways (ERK/p38 MAPK).

Main Results:

  • DIRAS2 expression is altered during different phases of epilepsy.
  • DIRAS2 overexpression reduces seizure susceptibility and activity.
  • DIRAS2 knockdown exacerbates ferroptosis, while overexpression protects against it.
  • DIRAS2 regulates ferroptosis by inhibiting the ERK/p38 MAPK pathway.
  • DIRAS2 modulates the neuronal E/I ratio, alleviating hyperexcitability.

Conclusions:

  • DIRAS2 plays a significant role in epilepsy pathogenesis.
  • DIRAS2 influences neuronal E/I balance and ferroptosis.
  • DIRAS2 represents a potential therapeutic target for epilepsy treatment.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K